Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
September 28, 2023
Earnings Call Speaker Segments
Operator
operatorHello, and welcome to the conference call on Palatin's operating results for Q4 and the close of fiscal year 2023. Right now, everyone is in a listen-only mode. After the formal presentation, there will be a question and answer session. Should you need operator assistance at any point during the call, just press star zero on your phone's keypad. Please be aware that this call is being recorded. Before we get to our remarks, I want to point out that anything Palatin states that is not a historical fact could be a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements about Palatin's prospects, please weigh those risks and uncertainties carefully. Now I'd like to hand the call over to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and thanks for joining Palatin's Q4 and fiscal year-end 2023 call. This is Dr. Carl Spana, CEO and President of Palatin. Joining me today is Steve Wills, Palatin's Executive Vice President, Chief Financial Officer, and Chief Operating Officer. At this point I'll hand things over to Steve, who'll provide the financial and operating update.
Steve Wills
executiveThank you, Carl. Thanks, Carl, and good morning and good afternoon, everyone. I'll begin with Vyleesi. As a reminder, Vyleesi is the commercial product we have that's FDA-approved for premenopausal women who have hypoactive sexual desire disorder, or HSDD. The aim of the Vyleesi program is to show commercial product value in the marketplace. With 6 consecutive quarters of double-digit growth, which we're gonna talk about shortly, I think we are doing that. But the objective is to relicense the US rights to a committed women's healthcare company, and that process is advancing. When I say nicely, we do expect that there will be a transaction that we will strongly consider, later this year. More about that as we move forward. Specifically, for the fiscal Q4, ended June 30th, 2023, Vyleesi gross product sales amounted to $4.1 million. This was an increase of 20% over the prior quarter and an increase of 78% over the comparable quarter last year. Net product revenue of $1.8 million increased 47% over the prior quarter and increased 128% over the comparable quarter last year. Total prescriptions dispensed increased 16% over the prior quarter and increased 92% over the comparable quarter last year. All the value metrics are moving in a positive direction.
Steve Wills
executiveWhen it comes to refill rates, commercial insurance reimbursement, and net revenue for each prescription dispense, we kept seeing strong results and trends compared with both the prior quarter and the same quarter a year ago. Turning to Vyleesi licensees outside the U.S.: Fosun Pharma, which holds Palatin's Vyleesi license in China, booked its first sale in China's Hainan Province. In South Korea, Palatin's Vyleesi licensee Kwangdong Pharmaceutical finished enrolling patients in its phase III clinical trial, which is assessing how efficacious and safe Vyleesi is in premenopausal women with HSDD. Results from that trial are presently expected by calendar year end, and a regulatory submission could come in the H1 of calendar year 2024. On another distribution front, Palatin struck a strategic partnership with UpScript Health, a leading direct-to-consumer telemedicine company that provides telemedicine services to pharmaceutical and medical technology companies. From an awareness standpoint, we expect the reach for Vyleesi to grow over the quarters ahead. Now to the financial update. For the Q4, and I will also point out certain results for the fiscal year ended June 30th, 2023. On revenue: total revenue is made up of gross product sales of Vyleesi, net of expenses, allowances, and accruals, plus license and contract revenue. As I noted, Vyleesi gross product sales to pharmacy distributors for the quarter ended June 30th, 2023, came to $4.1 million, with net product revenue of $1.8 million, versus gross product sales of $2.3 million and net product revenue of $0.8 million in the comparable quarter last year.
Steve Wills
executiveGross product sales rose 78%, while net product revenue climbed 128% versus the same quarter a year earlier. Now on to operating expenses. For Q4, which closed June 30th, 2023, total operating expenses came in at $12.6 million, versus $13.9 million in the comparable quarter of last year. That decline in operating expenses stemmed primarily from expense recognition during the fiscal year ended June 30th, 2022, tied to the sale and issuance of our Series B and Series C redeemable convertible preferred stock, and secondarily from reduced spending on our Vyleesi marketing efforts in fiscal 2023. I'd like to add a point about that $12.6 million — again, for Q4 ended June 30th, 2023 — this $12.6 million in operating expenses is in fact higher than what we had, so to speak, projected internally, and the reason is that we pushed our programs forward, chiefly our phase III dry eye disease trial, which we reported on recently, and which reached full enrollment. That full enrollment set off a milestone, and that milestone set off an expense and a payment. But I should note that this $12.6 million of operating expenses for the June 30th quarter — over the coming several quarters, that figure, those operating expenses, will be substantially below $12.6 million.
Steve Wills
executiveTo reiterate, we moved the programs forward and achieved certain milestones. That will bring somewhat higher costs. Timing problems of that kind are always going to come up. Now let me turn to cash flows. For the quarter that closed on June 30th, 2023, Palatin's net cash used in operations came to $9.6 million, versus $7.7 million of net cash used in operations during the matching period in 2022. Once more, the cause is what I just described above. We incurred somewhat larger expenses because the programs moved ahead, which is a good thing, and because certain milestones landed in the quarter ending June thirtieth. For the fiscal year ending June, June 30th — this covers the whole fiscal year — Palatin's net cash used in operations was $28.4 million, versus $29.9 million of net cash used in operations in the matching period in 2022. That drop in net cash used in operations, which is not a meaningful figure, was honestly attributable to several items, among them differing spending levels for Vyleesi, but also we did recognize some — a sale of some net operating losses to the state of New Jersey, which produced over $4 million in non-dilutive financing. Wrapping up the financials with the net loss and the cash position.
Steve Wills
executiveFor the quarter and fiscal year that closed on June 30th, 2023, Palatin posted a net loss of $10.7 million. To repeat, that figure was for the quarter, while the full year came in at $27.7 million — versus net losses of $12.8 million and $36.2 million, respectively, across the matching periods in 2022. On our cash position: as of June 30th, 2023, Palatin held roughly $11 million in cash, cash equivalents, and marketable securities, along with $2.9 million of accounts receivable. Those receivables are 100% good. Every one of those funds came in during the July, August timeframe. Compare that with cash and cash equivalents of $19.6 million plus $1.7 million in accounts receivables as of March 31st, 2023. You might say, "Hey, those accounts receivables ticked up a bit." Well, we're selling more. All good. Under our current operating plan, we believe existing cash, cash equivalents, and marketable securities and receivables will be enough to fund currently anticipated operating expenses through calendar year 2023. One thing worth noting: I do want to highlight that Palatin's audited financial statements for the year ended June 30th, 2023, to be included in the annual report on Form 10-K, do include an audit report from our independent registered public accounting firm, KPMG, that contains a going concern explanatory paragraph, which we have had for quite some time.
Steve Wills
executiveHaving said that, I'll hand things back to Carl so he can go into more granular detail on our exciting development and commercial programs. Carl?
Carl Spana
executiveThank you, Steve. Throughout 2023, we kept executing well on our strategy of creating novel therapeutics that work by activating the melanocortin system. As I've said before, our focus is on making the melanocortin system a target for medicines that are safe and effective in treating inflammatory and autoimmune diseases, and on building a pipeline of highly effective drugs with safety that is unparalleled. A key part of our strategy is deepening our knowledge of how the melanocortin system functions in stress responses, inflammation, and tissue repair. Our research work is gaining recognition through the many peer-reviewed and scientific presentations given by our scientists and academic collaborators. Thanks to our research efforts, we've been able to spot opportunities for novel, innovative therapeutics and to design better clinical trials, and those efforts are a key support for our business development activities. We have three active clinical programs built on melanocortin agonists that came out of our research efforts. As Steve mentioned, we're very pleased to have finished enrolling patients in the PL-9643, MELODY-1, phase III study in dry eye disease, and we're working to deliver top-line data before calendar year end. Our phase II study evaluating oral PL-8177, a selective melanocortin-one receptor agonist in ulcerative colitis patients, remains on track to finish patient enrollment by calendar year end, with interim assessment data as early as calendar year end.
Carl Spana
executiveBREAKOUT — that's our phase II open-label trial involving diabetic patients who have kidney disease — remains on schedule to deliver top-line results during Q1 of 2024. A few other fourth-quarter and full-year 2023 highlights include the following: Commercially, we're happy to see Vyleesi posting quarter-over-quarter double-digit gains on every value metric. In particular, net product revenue rose 47%, while prescription dispensed grew 16% versus the prior quarter. It's exciting that Vyleesi's quarterly net product revenue keeps coming in above its quarterly operating expenses — in other words, we make some money. Building on our commercial work in sexual dysfunction, we've created a co-formulation combining bremelanotide, our melanocortin receptor 4 agonist, with a phosphodiesterase 5 inhibitor. It's intended as a treatment for men with erectile dysfunction who have failed current PDE5 inhibitor therapy. As a side note, bremelanotide is the active ingredient in Vyleesi, and phosphodiesterase five inhibitors, or PDE5 inhibitors, include drugs like Viagra, Cialis, or Levitra — these are the standard of care for men with erectile dysfunction. You may not know this, but roughly 35% of men with erectile dysfunction fail or respond inadequately to current treatments, and they represent a very large underserved market.
Carl Spana
executiveFor these patients, the sole therapeutic choices are highly invasive—things like penile injections or penile implants. Clinical trials we ran earlier demonstrated synergistic effects when bremelanotide is combined with a PDE5 inhibitor for treating erectile dysfunction. This novel formulation's commercial development is backed by the sizable market opportunity and our clinical work, and we plan to start clinical programs as early as the close of this year. Impressive progress keeps coming from our ocular programs. As we have said, MELODY-1 has full enrollment, and we anticipate data by year-end. The emerging product profile for PL-9643 excites us greatly—it stands highly differentiated from current dry eye disease treatments, offering excellent ocular tolerability and broad efficacy that we believe will position PL-9643 as the leading therapy for dry eye disease. At the annual meeting of the Association for Research in Vision and Ophthalmology, also known as ARVO, we presented data from the lead-in population analysis of the MELODY-1 phase III trial, where PL-9643 showed broad efficacy and statistical significance, separation across multiple signs and symptoms of dry eye disease, and an excellent ocular tolerability and safety profile with no—I repeat, no—ocular adverse events. Setting the primary sign and symptom endpoints, the hierarchical ordering of secondary endpoints, the analytical methods and the sample size for the double-blind segment of MELODY-1 was possible with confidence because this analysis was extremely important.
Carl Spana
executiveWe're really enthusiastic about the data that's emerging, and we feel we've taken every step possible to lower the risk for this trial, and we're expecting a strongly positive result. We also shared data at ARVO on PL-9588, our melanocortin-based glaucoma treatment. In preclinical work, PL-9588 demonstrated competitive effects in lowering intraocular pressure from a single topical dose, with an effect size comparable to the positive controls latanoprost and timolol, which rank among the treatments currently in use, and those effects lasted as long as 24 hours. Importantly, we've also demonstrated optic nerve protection effects, something we believe next-generation glaucoma therapies will require, so this compound doesn't just reduce intraocular pressure — it actually protects the optic nerve. As we get ready to move this important program forward, we've already begun regulatory discussions with the FDA. Our research efforts likewise achieved meaningful progress, with numerous presentations at scientific meetings, publications, and peer-reviewed journals. Our know-how in the melanocortin system and our innovative clinical programs are fueling our business development activities. We have several ongoing conversations with potential partners regarding our programs, and we stay optimistic that we'll finalize one or more partnerships to help move some of these highly exciting programs ahead.
Carl Spana
executiveLooking ahead to fiscal 2024, there are substantial opportunities for us to create value. We'll have data arriving from three clinical trials, the launch of two new clinical programs, ongoing growth and partnerships for Vyleesi, and progress on Vyleesi by our partners in South Korea and China. Steve and I want to thank you for joining the Palatin Q4 and fiscal year-end 2023 conference call. More details about our science and clinical programs are available on our website, www.palatin.com, and further information about Vyleesi can be found at the vyleesi.com website. Thank you. We'll now take questions.
Operator
operatorThanks a lot. We're going to move into a question-and-answer session now. Should you wish to pose a question, hit star one on your phone's keypad. A confirmation tone will let you know that your line has joined the question queue. If you'd rather take your question out of the queue, you can press star two. Anyone on speaker equipment might need to lift the handset before pressing the star keys. Kindly hold on a moment while we poll for questions. Thank you. Our first question comes from Joe Pantginis of H.C. Wainwright. Joe, your line is open.
Joe Pantginis
analystMorning, everyone. Thanks for taking the time. I've got a couple of questions, if that's alright, but before I get to those — best of luck closing the Vyleesi transaction. It's clearly something people have been waiting for, and you've kept showing solid traction, since you haven't had to put much in on your side while DTC is delivering some encouraging results, so good luck with all of that. First, turning to PL-8177, I wanted to dig a bit deeper into the data coming up, which I believe is expected around year-end or possibly rolling into the start of the year. For that interim look in UC patients, what kind of data do you think you'll be in a position to show us?
Carl Spana
executiveRight, so that's the primary endpoint data. This is a study with 8 weeks of treatment, clearly active against placebo, and the main thing we're assessing is a colonoscopy score — an endoscopic score — so we're after grading, we're eager to see endoscopic lesions, and also, you know, lesions going down and showing clear signs of healing, according to the Mayo Endoscopic Sub Score.
Joe Pantginis
analystUnderstood, understood. Then, clearly, I mean, turning back to Vyleesi briefly, though more regarding the combination you announced recently and provided further details on today involving the PDE5 combination. Anything additional on the design you're considering and what sort of enrollment expectations you might need in order to generate, let's say, data?
Carl Spana
executiveOkay, a few points. In that first trial we plan to run, the drugs will be administered together, so it won't involve the co-formulation. What this study aims to do is establish the correct ratio of bremelanotide to the PDE5 inhibitor for patients who have failed treatment. The co-formulation would be employed in the second study, the follow-up to that one, where we're able to reduce the number of combinations we need to examine. Enrollment in these trials goes very quickly. We likely have two clinical sites, specifically Philadelphia and New York. We're working with—one benefit, you know, is that we've clearly had a very lengthy track record of working in sexual dysfunction and ED as well. When we went back to some of our key investigators, they were pretty excited about running this study. As they told us, you know, there hasn't been any new innovation in erectile dysfunction in 30 years, and these patients truly have no alternative, so I'd expect enrollment in the study to be extremely fast.
Joe Pantginis
analystAlright, good. So then, you know what, let me return to Vyleesi on its own for a moment. Look, I think you folks have the capability to, as I said, get transactions done, since obviously, you know, the ex-U.S. deals are already in place as well, along with upcoming news, as you mentioned. I suppose let me take the other side of that argument. Nothing in this world is assured until signatures are on the page. So, you know, at the other end of things, if you don't, let's say, license it in the U.S., what possible plans or scenarios would you consider for Vyleesi, and, you know, what type of potential investment might you or might you not be looking at?
Carl Spana
executiveOkay, thanks for that question, Joe. Look, internally, we're extremely happy with how things have turned out. That's six quarters in a row now of double-digit growth, and more importantly, we aren't losing money. As a matter of fact, Vyleesi is making money for us. Our infrastructure is quite lean. Targeted profitable growth is the plan, and we're executing on it. I mean, we posted $1.8 million in net sales. We expect that figure to rise in Q3 and Q4, and at some point, you know, if we don't pull the trigger — and we have options. We 100% have options when it comes to pulling a trigger on a transaction for Vyleesi. It's always that trade-off between value now and potentially value later. There are many things we could do, and we are weighing them, but we're trying to strike a balance on, well, if you do something here now, how does that impact the potential transaction, if it's going to be a quarter or two later, and a lot of that centers on distribution expansion. Adding a sales force or feet on the ground is not something we're considering, but there are many more outlets out there, particularly around telehealth, telemedicine, i.e., with UpScript, that would like to distribute Vyleesi, so we are pushing those kinds of discussions forward.
Carl Spana
executiveWhat I mean is, once the transaction closes, we hand that product to them at an agreed price, and they handle selling it in that market. That won't happen. It won't interfere with our current operations. Many of those outlets run on a cash-only basis, but that's genuinely a market and a patient population we can't reach today given how our infrastructure and spending are structured. So, circling back, we have very substantial — we have several paths that could create considerable value and lift revenue, yet none of them will lead us to put money into Vyleesi where we aren't earning a return. We've been generating profit on Vyleesi over the last several quarters, and whatever we pursue, we'll keep to that same kind of approach.
Joe Pantginis
analystUnderstood. Thanks for the additional detail, everyone.
Operator
operatorThanks a lot. The next question comes from Michael Higgins at Ladenburg Thalmann. Michael, your line is open.
Michael Higgins
analystThanks, Operator. Congratulations, guys. Appreciate you taking the question. Congrats, and keep up the continued progress with Vyleesi and the rest of the pipeline. Just to follow up, if I could, on the erectile dysfunction program. Joe was asking some smart questions about the trial. Just wanna ask one more, if I could, on design, size, that type of thing, what you are able to share at this time, or do you plan to wait until you start that program?
Carl Spana
executiveNo, I mean, look, these studies are fairly uncomplicated. As I mentioned, they're dose-finding trials meant to determine the right ratio in patients who haven't responded to PDE5 inhibitor therapy. So what you have is a fixed dose of the PDE5 inhibitor plus escalating doses of bremelanotide added on top, in patients for whom PDE5 inhibitor therapy has failed, so there's really no trick involved here. They're quite uncomplicated. The metrics we rely on for measuring efficacy are well established, so as I said, these trials enroll very rapidly, and there are plenty of patients available. But bear in mind, we've also held some conversations with potential third parties regarding this, and interest is high. As you know, many companies are out there distributing PDE5 inhibitors on a cash basis. A lot of those companies have by now added reimbursement—insurance reimbursement—and they're hunting for a new product in the ED space, so this is a situation where I'd expect we could transact relatively early in the development process.
Michael Higgins
analystThat's a fair point. We will review the other phase II studies that have been completed. It has been a great many years, but that should give us some indication. It sounds as though you have some data on the combination of bremelanotide and a PDE5 inhibitor. If that is the case, how do you intend to share it?
Carl Spana
executiveWell, those figures are published. That data is out there. It's in the public domain. You can find it.
Michael Higgins
analystGot it. Right, I have those. I was thinking there might be a few more.
Carl Spana
executiveIf not, there are other publications from third-party groups—not Palatin—that have examined monotherapy, for instance with bremelanotide in PDE5 inhibitor failure, demonstrating that a significant percentage, a third of the patients that fail PDE5 inhibitor therapy can be rescued on monotherapy alone so there's a very strong precedent here. You know, and I think this is a program that in our minds represents has a very low clinical risk. You have FDA-approved agents that are, you know, with obviously, the PDE5 inhibitors work. Obviously, we know they work in men, and we've shown we've treated almost, you know, 2,500 men with erectile dysfunction with bremelanotide. I think there's very strong clinical precedence here and more importantly, there's a very high medical need here. I mean, a lot of these, there's a lot of men out there that just don't have other options so we like it from the standpoint, I think both the commercial side and, and the development side are relatively low risk.
Michael Higgins
analystYeah, that data looks great. We’ll mention it again in our notes, but here’s another exciting program coming up, possibly in obesity, since it involves melanocortin, a target that you have for your pipeline. Do you have any update or feedback for us regarding interest in the obesity space?
Carl Spana
executiveOkay, I'll mention just a handful of these points. Steve is staring at me — shooting me a glare. I'll touch on a few items here. Lots of you, naturally, are aware that we've maintained quite a keen interest in obesity, partly because many folks listening to this call are somewhat younger and haven't been in the field as long as we have. The melanocortin-4 receptor was likely the earliest validated target for treating obesity, and most of the bigger firms did run programs hunting for small molecules, and sadly, that target is extremely tough for small molecules, though it works very well for peptides. As I know you're aware, Michael, you follow setmelanotide, the Rhythm product. We've published data from 2 studies we ran with bremelanotide, demonstrating quite impressive weight loss with bremelanotide in obese patients. We also enjoyed a very productive partnership with AstraZeneca spanning a number of years, so we possess enormous expertise regarding the melanocortin system's part in controlling food intake and obesity, with outstanding compounds and solid insight into developing small molecules. We're pretty enthusiastic about the present expansion of that marketplace, and there's a coming attraction.
Carl Spana
executiveObesity Week is coming up in a couple of weeks. I'm sure you're well aware of that, and so I would just say stay tuned.
Michael Higgins
analystAbsolutely. I will be there in Dallas for that, so I'm looking forward to it. Here's a question for you — the last one — and I can either hop back into the queue or continue. Just let me know. But for now, one final item anyway, and it concerns Vyleesi. Hearing what you said about the program and your discussion, Steve, with Joe regarding the path forward, it strikes me that if you achieve successful advancement in erectile dysfunction, you could position this as the sole medication for sexual dysfunction in both men and women. That would be unique, and it would draw a lot of attention. Do you have any thoughts on extending the program a bit longer, at least through some phase II data from a combination study?
Carl Spana
executiveWell, since you raised the subject of sexual dysfunction, some clinicians are also prescribing it for men with other kinds of sexual dysfunction — sexual dysfunction caused by SSRI use, low desire stemming from stress factors and other things — and it performs very well in those cases, and there may be some data coming at a meeting in the near future on that, so I personally believe this will become the number one treatment for sexual dysfunction in both men and women.
Steve Wills
executiveLet me jump in on that too, Michael. Look, we couldn't be more thrilled with the results we've seen, and with some of the things we won't get into today regarding where we believe—with the right investment—there's very significant normative value for patients, and for different types of patients, whether pre, post, or the male population you're referring to. 100% we are analyzing and assessing that, and we have to weigh it against, okay, you have several potential transactions you might be able to move forward with, and even if you feel that strongly—and we do—we think there's a lot of value there. The longer we hold on to Vyleesi and keep seeing these results, the more value you're going to get down the road, but we also have to balance it in a realistic way. This is a tough landscape, right? We're a small biotech company, and we're getting into those cash numbers where we may have to do something over the next several quarters, and the dilutive financing for some deals out there is not pretty, and we're not going to do some of those deals that are being done.
Steve Wills
executiveI'm not trying to criticize anyone or make a guess. You know, there are various factors they consider, but we won't be pursuing some of those deals that are getting done that I don't believe a company can bounce back from. That said, we have to weigh, "Hey, I have non-dilutive financing," you know, and regardless, it's going to be, you know, it's going to be a solid deal. But timing matters a great deal to us, and we do factor in the market landscape when it comes to raising funds. A brief break on that after the coke and the hot dog. You know, that's not the only possible collaboration we have that could come to pass and I'm not just, you know, stepping away from Vyleesi, which we have a lot of confidence in. Dry eye disease, we have, obviously, the data is coming out. You know, we're hoping for that nice Christmas present, during the holidays there. But our other programs have interest, and, you know, that's also something, you know, often, the more, the further along you bring your program, as long as everything's working well, you know, safety, efficacy, tolerability, those sorts of things, more than likely, the greater value you're going to get but you have to balance, you know, where your company stands and, and doing what's right for the shareholders regarding, you know, non-dilutive versus dilutive financing.
Steve Wills
executiveBut I want to be clear that we do have other interest. Carl and I try to speak with as many people as we can, and I think it was either you or Joe who asked about the PL-8177 ulcerative colitis endpoints. Listen, those endpoints are based on a lot of conversation, not only with KOLs but also with companies that would be interested. It's a nice approach to start with, "Hey, if we get the first phase, do you care?" And we've changed the protocol based on that kind of feedback, both with the dry eye disease and with the ulcerative colitis. But to be clear, we have multiple shots on goal for cash flow coming in, 100% separate from a potential equity raise.
Michael Higgins
analystAppreciate that feedback, thank you. If I could just follow up — on the earlier pipeline programs, and cash as well, you mentioned PL-9643 beginning in a different indication, potentially by year-end. It doesn't sound as though that's going to happen. I just wanted to raise that point. Is that still.
Carl Spana
executiveAbsolutely, Michael. Yes, we would. For the ocular area, we're pursuing a distinct compound aimed at glaucoma. That's the next eye-related program which, depending on resources—naturally—we'd move ahead with. We've already begun talking with the FDA about how a trial might be designed and the kinds of preclinical work we'd require, and we expect their response before the end of the year, so that's likely the direction we'd take. Partly that's because our aim for PL-9643 as it emerges from MELODY-1 would really be to secure a partner, and clearly under a partnership, every opportunity for PL-9643 would be captured by that partner. That's the reason we've restrained ourselves on certain things we could pursue there, and instead we're concentrating on glaucoma as well as the back of the eye with 9654, which we haven't discussed—yet there's enormous interest in our retinal programs. Although they remain preclinical, they do offer a novel mechanism, and lots of people—lots of investors—don't keep up with the scientific literature, the posters, and the work we've been creating in that area, but the data is really quite compelling regarding how this molecular mechanism functions to shield the back of the eye from damage, and that directly connects to both retinal and glaucoma, which is why we're so enthusiastic.
Carl Spana
executiveI mean, take glaucoma—there isn’t any product available, for instance, that can both bring glaucoma pressure down and deliver neuroprotection, and that’s genuinely what’s required. When we consider how we pick these programs, you know, we really want to be sure these products stand apart clearly from what exists in the marketplace, and that they have a chance to become, you know, the top products in their category.
Michael Higgins
analystYeah, I'd definitely share that view on your back-of-the-eye programs. One thing we were wondering about as we came into this — and I'll build on that — is PL-9588. My understanding is that you're aiming to get an IND cleared by year-end, while also doing work on your subq formulation. Is there any update you can give us on that? Perhaps that overlaps with PL-9654, but.
Carl Spana
executiveSo we work through it. PL-9588, for glaucoma, is administered topically. There, once again, you know, how quickly these prototype programs advance depends purely on resources, correct? There's no—we face no obstacle to pushing that product ahead. The data is sufficient. We—the activities that we need are starting to happen. It comes down to, you know, as Steve was saying, you know, in a difficult landscape, we do have to balance things out, you know, we are, you know, balancing things out. But, you know, I think, I think we'll succeed in, in, in what we're doing, so I think the cash will take care of itself.
Michael Higgins
analystThanks for all the input, everyone. I appreciate it.
Operator
operatorThanks so much. It looks like there are no more questions waiting in the queue. At this point, I'll turn things back to Carl for any closing remarks.
Carl Spana
executiveWell, I want to express my appreciation to everyone for joining us for Palatin's Q4 and fiscal year end 2023 call. I believe that through our presentation and the questions from the analysts — which I think were hopefully illuminating — you've picked up a solid sense of how much depth Palatin can offer from a valuation perspective. And, you know, I recognize there can always be frustration and disconnects between valuation and opportunity, especially when it comes to microcap companies, but we definitely feel we're undervalued, and we're certainly going to work hard to fix that, and we believe we have all the right pieces in place to make that happen. So thank you. We look forward to continuing to keep you guys updated, and have a great day — and thank you on behalf of Steve and myself, and all the employees at Palatin.
Operator
operatorThank you so much. That brings today’s conference call to an end. At this point you’re welcome to hang up your phone lines, and we hope you have a wonderful day. We appreciate you taking part.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.